导航药物开发的复杂性用于炎症性肠道疾病
Sailish Honap1,2,3, Vipul Jairath4,5,6, Silvio Danese7
1Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK. shonap@nhs.net.
Nature reviews. Drug discovery
|May 22, 2024
概括
机器学习和组织工程的新方法可以改善炎症性肠病 (IBD) 的临床前药物开发. 创新的临床试验设计对于推进IBD治疗也至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 生物技术是生物技术.
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎和克罗恩病,是一种复杂的免疫媒介疾病,目前的治疗疗法治疗效率有限.
- 治疗进步的平原需要识别新的药物标和伴随生物标志物,用于患者分层.
- 在临床前阶段的高消耗率和临床试验的招募率下降阻碍了新的IBD治疗方法的开发.
研究的目的:
- 探索机器学习和组织工程在增强IBD临床前药物开发方面的潜力.
- 确定克服临床试验进展中的挑战的策略,包括招聘和设计.
- 提出创新方法,加速开发更有效的IBD疗法.
主要方法:
- 审查当前的治疗环境和IBD药物开发中的挑战.
- 检查在临床前研究中的机器学习和组织工程应用.
- 对影响临床试验进展和招聘因素的分析.
- 评估创新的临床试验设计,终端协调和数字技术集成.
主要成果:
- 机器学习和组织工程为改善临床前IBD研究和降低消耗率提供了有希望的途径.
- 重构临床试验设计,标准化终点和使用数字工具可以加速新型IBD病原体的进展.
- 在药物开发的每个阶段应对挑战是实现增量增长的关键.
结论:
- 整合先进的临床前技术和优化临床试验方法对于推进IBD治疗方法至关重要.
- 要克服IBD药物开发当前的局限性,需要从长椅到床边的多方面的方法.
- 利用技术和方法方面的创新可以为患有炎症性肠病的患者提供更有效的治疗方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115


